$REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Sushil Patel
CEO
479
Employees
$9.98
Current Price
$629.87M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $110,880.00 | 12,000 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $110,880.00 | 12,000 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 7 | $585,026.88 | 105,336 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 7 | $585,026.88 | 105,336 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 8 | $637,091.88 | 111,836 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 12,000 | $9.24 | $110,880.00 | View Details |
| May 18, 2026 | Xynos Konstantinos Chief Medical Officer | Sale | 14,023 | $5.08 | $71,236.84 | View Details |
| May 18, 2026 | Schwendenman Andrew Chief Accounting Officer | Sale | 7,894 | $5.08 | $40,101.52 | View Details |
| May 18, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 8,626 | $5.08 | $43,820.08 | View Details |
| May 18, 2026 | Astley-Sparke Philip Director | Sale | 17,657 | $5.08 | $89,697.56 | View Details |
| May 18, 2026 | Patel Sushil Director | Sale | 37,324 | $5.08 | $189,605.92 | View Details |
| May 18, 2026 | Hill Emily Luisa Chief Financial Officer | Sale | 7,812 | $5.08 | $39,684.96 | View Details |
| Apr 2, 2026 | Sarchi Christopher Chief Commercial Officer | Sale | 6,500 | $8.01 | $52,065.00 | View Details |
5 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history